AR023628A1 - Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que - Google Patents
Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en queInfo
- Publication number
- AR023628A1 AR023628A1 ARP990102086A ARP990102086A AR023628A1 AR 023628 A1 AR023628 A1 AR 023628A1 AR P990102086 A ARP990102086 A AR P990102086A AR P990102086 A ARP990102086 A AR P990102086A AR 023628 A1 AR023628 A1 AR 023628A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- agent
- stimulate
- increase
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Abstract
Uso de un agente efectivo para incrementar el numero de células hematopoyéticas o células sanguíneas maduras de formula (1) en donde m es un entero entre 0y 10, inclusive; A y A1 son residuos L-aminoácidos (para glicina no hay dicha distincion), de manera que el A en cada unidad de repeticion entre paréntesispuede ser un residuo de aminoácido diferente; el C enlazado a B se encuentra en la configuracion L; los enlaces A y N, A1 y C, y entre A1 y N, son enlacespeptídicos; y cada X1 y X2 es, independientemente, un grupo hidroxilo o un grupo capaz de ser hidrolizado a un grupo hidroxilo en solucion acuosa a pHfisiologico, para la preparacion de un medicamento util para estimular la hematopoyesis, que comprende una cantidad efectiva de dicho agente y al menos unvehículo farmacéuticamente aceptable; uso de un agente de formula (1) para la preparacion de un medicamento util para incrementar el numero de célulashematopoyéticas o células sanguíneas maduras que acorta el tiempo en que un sujetotiene un nivel anormalmente bajo de células hematopoyéticas o sanguíneasmaduras como resultado del tratamiento de un inhibidor de células hematopoyéticas; uso de un agente de Formula (1) para preparar un medicamento util parapreparar a un sujeto para el tratamiento con un inhibidor de células hematopoyéticas donde se estimula la produccion de factor de crecimiento y dichomedicamento es para ser administrado al sujeto antes de que el sujeto reciba el inhibidor de células hematopoyéticas; métodopara estimular la produccion defactor de crecimiento por parte de células estromales, que comprende: poner en contacto células estromales con un agente en una cantidad efectiva paraestimular la produccion de factor de crecimiento por parte de las células estromales, en donde el agente es un compuesto de Formula (1); método in vitro paraestimular la produccion de factor de crecimiento por parte de células estromales, que comprende: poner en contacto células estromales con un agente en unacantidadefectiva para estimular la produccion de factor de crecimiento por parte de las células estromales, en donde el agente es un compuesto de Formula (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8412898P | 1998-05-04 | 1998-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023628A1 true AR023628A1 (es) | 2002-09-04 |
Family
ID=22183048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990102086A AR023628A1 (es) | 1998-05-04 | 1999-05-04 | Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que |
Country Status (15)
Country | Link |
---|---|
US (4) | US6300314B1 (es) |
EP (1) | EP1075266A1 (es) |
JP (1) | JP2002513762A (es) |
KR (1) | KR20010052302A (es) |
AR (1) | AR023628A1 (es) |
AU (2) | AU770319C (es) |
BR (1) | BR9910251A (es) |
CA (1) | CA2331122A1 (es) |
IL (1) | IL139247A0 (es) |
MY (1) | MY132924A (es) |
NO (1) | NO20005488L (es) |
NZ (1) | NZ507730A (es) |
PE (1) | PE20000481A1 (es) |
TW (1) | TWI252107B (es) |
WO (1) | WO1999056753A1 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258597B1 (en) * | 1997-09-29 | 2001-07-10 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
JP2002513762A (ja) * | 1998-05-04 | 2002-05-14 | ポイント セラピューティクス, インコーポレイテッド | 造血刺激 |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
KR100915482B1 (ko) | 2000-12-06 | 2009-09-03 | 하리리 로버트 제이 | 태반 줄기 세포의 회수 방법 |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
EP1352655A4 (en) | 2001-01-16 | 2006-11-02 | Nippon Kayaku Kk | REMEDIES FOR THE TREATMENT OF BONE MARROW REMOVAL AND INFECTIOUS DISEASES AND AGENTS FOR INCREASING LEUKOCYTIC CONCENTRATION OF BLOOD |
EP1362095B1 (en) * | 2001-02-14 | 2015-05-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
AU2002360453C1 (en) * | 2001-11-26 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Methods for treating autoimmune disorders, and reagents related thereto |
EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
JP4927316B2 (ja) * | 2001-12-17 | 2012-05-09 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 磁気共鳴方法 |
WO2003092605A2 (en) * | 2002-04-30 | 2003-11-13 | Trustees Of Tufts College | Protease inhibitors |
JP2006507352A (ja) * | 2002-07-09 | 2006-03-02 | ポイント セラピューティクス, インコーポレイテッド | イソロイシンのボロプロリン化合物に関する方法および組成物 |
EP1571910A4 (en) | 2002-11-26 | 2009-10-28 | Anthrogenesis Corp | CYTOTHERAPEUTIC AGENTS, CYTOTHERAPEUTIC UNITS AND METHODS OF TREATMENT IN WHICH THEY INTERVENE |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
ES2524916T3 (es) * | 2003-11-12 | 2014-12-15 | Sino-Med International Alliance, Inc. | Compuestos heterocíclicos de ácido borónico |
BRPI0507972A (pt) * | 2004-02-23 | 2007-07-24 | Tufts College | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
WO2006052960A2 (en) * | 2004-11-08 | 2006-05-18 | The General Hospital Corporation | METHODS AND COMPOSITIONS FOR INCREASING STEM CELL HOMING USING Gαs ACTIVATORS |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
ES2452595T3 (es) | 2005-10-13 | 2014-04-02 | Anthrogenesis Corporation | Inmunomodulación usando células madre de la placenta |
PL2471904T3 (pl) | 2005-12-29 | 2019-08-30 | Celularity, Inc. | Populacje komórek macierzystych łożyska |
US8455250B2 (en) | 2005-12-29 | 2013-06-04 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
WO2008094689A2 (en) * | 2007-02-01 | 2008-08-07 | Nephrogen, Llc | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
US20080195007A1 (en) * | 2007-02-12 | 2008-08-14 | Yury Podrazhansky | Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms |
AU2008216749B2 (en) | 2007-02-12 | 2014-03-13 | Celularity Inc. | Treatment of inflammatory diseases using placental stem cells |
US7674691B2 (en) * | 2007-03-07 | 2010-03-09 | International Business Machines Corporation | Method of manufacturing an electrical antifuse |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
EP2783692B1 (en) | 2007-09-28 | 2019-01-02 | Celularity, Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
CN105796602A (zh) | 2008-08-20 | 2016-07-27 | 人类起源公司 | 利用分离的胎盘细胞治疗中风 |
MX2011001990A (es) | 2008-08-20 | 2011-03-29 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas. |
CN102176919A (zh) | 2008-08-22 | 2011-09-07 | 人类起源公司 | 用胎盘细胞群治疗骨缺损的方法和组合物 |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
KR20110086176A (ko) | 2008-11-19 | 2011-07-27 | 안트로제네시스 코포레이션 | 양막 유래 부착성 세포 |
CA2767014C (en) | 2009-07-02 | 2022-01-25 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
WO2011028455A1 (en) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
CA2784799C (en) | 2009-12-30 | 2014-06-10 | Shanghai Fochon Pharmaceutical Co Ltd | Certain dipeptidyl peptidase inhibtors |
ES2646750T3 (es) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias |
US8853212B2 (en) | 2010-02-22 | 2014-10-07 | Merck Sharp & Dohme Corp | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
SI2556145T1 (sl) | 2010-04-07 | 2017-01-31 | Anthrogenesis Corporation | Angiogeneza z uporabo placentnih matičnih celic |
KR20130092394A (ko) | 2010-04-08 | 2013-08-20 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 사용한 사르코이드증의 치료 |
EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
NZ605505A (en) | 2010-07-13 | 2015-02-27 | Anthrogenesis Corp | Methods of generating natural killer cells |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
AR093183A1 (es) | 2010-12-31 | 2015-05-27 | Anthrogenesis Corp | Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3443968A1 (en) | 2011-06-01 | 2019-02-20 | Celularity, Inc. | Treatment of pain using placental stem cells |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2753334B1 (en) | 2011-08-30 | 2022-10-19 | Trustees Of Tufts College | Fap-activated proteasome inhibitors for treating solid tumors |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
EP2814485A4 (en) | 2012-02-17 | 2015-08-26 | Merck Sharp & Dohme | DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
EP2874622A4 (en) | 2012-07-23 | 2015-12-30 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE158109C (es) | ||||
DE270382C (es) | ||||
DE296075C (es) | ||||
US4318904A (en) | 1980-04-25 | 1982-03-09 | Research Corporation | Peptide affinity labels for thrombin and other trypsin-like proteases |
US4443609A (en) | 1980-05-19 | 1984-04-17 | Petrolite Corporation | Tetrahydrothiazole phosphonic acids or esters thereof |
DD158109A1 (de) | 1981-04-10 | 1982-12-29 | Gunter Fischer | Verfahren zur hemmung der katalytischen aktivitaet von peptidhydrolasen |
US4582821A (en) | 1983-11-16 | 1986-04-15 | E. I. Du Pont De Nemours And Company | Inhibition of cyclic nucleotide independent protein kinases |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US4636492A (en) | 1984-08-29 | 1987-01-13 | E. I. Du Pont De Nemours And Company | Inhibition of viral protease activity by peptide halomethyl ketones |
US4652552A (en) | 1984-09-10 | 1987-03-24 | E. I. Du Pont De Nemours And Company | Tetrapeptide methyl ketone inhibitors of viral proteases |
US4644055A (en) | 1984-12-17 | 1987-02-17 | E. I. Du Pont De Nemours And Company | Method for preparing specific inhibitors of virus-specified proteases |
US4664262A (en) * | 1985-11-26 | 1987-05-12 | White Pamela J | Pill dispensing system |
DD270382A1 (de) | 1986-10-31 | 1989-07-26 | Univ Halle Wittenberg | Verfahren zur kolorimetrischen bestimmung von dipeptidylpeptidase iv mittels dipeptidhydraziden |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
EP0398880A4 (en) | 1988-01-04 | 1990-12-27 | E.I. Du Pont De Nemours And Company | Multiple stage affinity process for isolation of specific cells from a cell mixture |
US4963655A (en) | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
US5215926A (en) | 1988-06-03 | 1993-06-01 | Cellpro, Inc. | Procedure for designing efficient affinity cell separation processes |
DE68924850T2 (de) | 1988-06-14 | 1996-10-10 | Cell Med Inc | Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. |
IL91307A0 (en) | 1988-08-24 | 1990-03-19 | Merck & Co Inc | Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them |
DE3840452A1 (de) | 1988-12-01 | 1990-06-07 | Hoechst Ag | (beta)-amino-boronsaeure-derivate |
DE3842197A1 (de) | 1988-12-15 | 1990-06-21 | Hoechst Ag | Rasch spaltbares substrat fuer die hiv-protease |
US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5635386A (en) | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
DD296075A5 (de) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
DE4033062A1 (de) | 1990-10-18 | 1992-04-23 | Merck Patent Gmbh | Aminosaeurederivate |
JPH05508624A (ja) | 1990-04-14 | 1993-12-02 | ニュー イングランド メデカル センター ホスピタルズ インク | ジペプチジル―アミノベプチダーゼ・4型の阻害剤 |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5378624A (en) | 1990-04-23 | 1995-01-03 | Cellpro, Incorporated | Methods for removing ligands from a particle surface |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
WO1991017767A1 (en) | 1990-05-21 | 1991-11-28 | New England Medical Center Hospitals, Inc. | Method of treating inhibition of dipeptidyl aminopeptidase type iv |
GB9017694D0 (en) | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
US5288707A (en) | 1990-08-13 | 1994-02-22 | Sandoz Ltd. | Borolysine peptidomimetics |
FR2668069B1 (fr) * | 1990-10-18 | 1993-02-05 | Dassault Avions | Dispositif, notamment autonome et portable, pour extraire de la chaleur d'une source chaude. |
WO1992012140A1 (en) | 1990-12-28 | 1992-07-23 | Georgia Tech Research Corporation | Peptides ketoamides, ketoacids, and ketoesters |
WO1992017490A1 (en) | 1991-04-04 | 1992-10-15 | The Upjohn Company | Phosphorus containing compounds as inhibitors of retroviruses |
IE922316A1 (en) | 1991-07-17 | 1993-01-27 | Smithkline Beecham Corp | Retroviral protease inhibitors |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
AU2468392A (en) | 1991-08-29 | 1993-04-05 | Cytel Corporation | Novel immunosuppressants |
WO1993008259A2 (en) * | 1991-10-22 | 1993-04-29 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
WO1993016102A1 (en) | 1992-02-06 | 1993-08-19 | Dana-Farber Cancer Institute, Inc. | Human cd26 and methods for use |
US5296604A (en) | 1992-05-15 | 1994-03-22 | Miles Inc. | Proline derivatives and compositions for their use as inhibitors of HIV protease |
WO1994003055A1 (en) | 1992-07-31 | 1994-02-17 | The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services | Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv |
US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
WO1994009132A1 (en) | 1992-08-21 | 1994-04-28 | Dana-Farber Cancer Institute, Inc. | Human cd26 and methods for use |
FR2701951B1 (fr) | 1993-02-24 | 1995-06-09 | Adir | Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
CA2153656A1 (en) | 1993-03-03 | 1994-09-15 | Nigel Scott Cook | Peptide boronic acid derivatives having protease inhibiting activity |
US5384410A (en) | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
AU6773994A (en) | 1993-04-23 | 1994-11-21 | Cellpro, Incorporated | Methods for enriching fetal progenitor cells from maternal blood |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
FR2707170A1 (fr) | 1993-06-04 | 1995-01-13 | Pasteur Institut | Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26. |
WO1995011689A1 (en) | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
NL9400309A (nl) | 1993-11-04 | 1995-06-01 | Eurogenetics Nv | Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5489025A (en) * | 1994-03-01 | 1996-02-06 | Romick; Jerome M. | Unit-dose medication dispenser and multiple-dispenser frame therefor |
FR2719049B1 (fr) | 1994-04-22 | 1996-06-14 | Pasteur Institut | Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules. |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
DE4416963C1 (de) | 1994-05-13 | 1995-07-13 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von enantiomerenreinen Diarylprolinolen |
WO1995034538A2 (en) | 1994-06-10 | 1995-12-21 | Universitaire Instelling Antwerpen | Purification of serine proteases and synthetic inhibitors thereof |
FR2721611B1 (fr) | 1994-06-22 | 1996-09-27 | Adir | Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent . |
JPH11501506A (ja) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
US5856571A (en) | 1995-06-07 | 1999-01-05 | Cellpro, Incorporated | Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto |
DE69614535T2 (de) | 1995-06-07 | 2002-06-06 | Aastrom Biosciences Inc | Vorrichtung und verfahren zum aufbewahren und zur züchtung biologischer zellen |
JP2000504209A (ja) * | 1995-12-29 | 2000-04-11 | エーエルジー カンパニー | 骨髄間質細胞の拡大増殖 |
US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
GB9624562D0 (en) | 1996-11-27 | 1997-01-15 | Zeneca Ltd | Peptide derivatives |
US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
US6258597B1 (en) | 1997-09-29 | 2001-07-10 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
JP2002513762A (ja) * | 1998-05-04 | 2002-05-14 | ポイント セラピューティクス, インコーポレイテッド | 造血刺激 |
WO2000010549A1 (en) | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
JP2006507352A (ja) | 2002-07-09 | 2006-03-02 | ポイント セラピューティクス, インコーポレイテッド | イソロイシンのボロプロリン化合物に関する方法および組成物 |
-
1999
- 1999-05-03 JP JP2000546778A patent/JP2002513762A/ja active Pending
- 1999-05-03 TW TW088107193A patent/TWI252107B/zh not_active IP Right Cessation
- 1999-05-03 BR BR9910251-0A patent/BR9910251A/pt not_active Application Discontinuation
- 1999-05-03 EP EP99921617A patent/EP1075266A1/en not_active Withdrawn
- 1999-05-03 CA CA002331122A patent/CA2331122A1/en not_active Abandoned
- 1999-05-03 KR KR1020007012223A patent/KR20010052302A/ko active Search and Examination
- 1999-05-03 WO PCT/US1999/009652 patent/WO1999056753A1/en not_active Application Discontinuation
- 1999-05-03 US US09/304,199 patent/US6300314B1/en not_active Expired - Fee Related
- 1999-05-03 IL IL13924799A patent/IL139247A0/xx unknown
- 1999-05-03 MY MYPI99001736A patent/MY132924A/en unknown
- 1999-05-03 NZ NZ507730A patent/NZ507730A/xx unknown
- 1999-05-03 AU AU38781/99A patent/AU770319C/en not_active Ceased
- 1999-05-04 AR ARP990102086A patent/AR023628A1/es unknown
- 1999-05-04 PE PE1999000365A patent/PE20000481A1/es not_active Application Discontinuation
-
2000
- 2000-10-31 NO NO20005488A patent/NO20005488L/no not_active Application Discontinuation
-
2001
- 2001-06-11 US US09/878,792 patent/US6770628B2/en not_active Expired - Fee Related
-
2004
- 2004-05-19 AU AU2004202138A patent/AU2004202138A1/en not_active Abandoned
- 2004-06-28 US US10/879,479 patent/US7067489B2/en not_active Expired - Fee Related
-
2006
- 2006-06-26 US US11/474,929 patent/US20070135354A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6770628B2 (en) | 2004-08-03 |
KR20010052302A (ko) | 2001-06-25 |
CA2331122A1 (en) | 1999-11-11 |
US20050037976A1 (en) | 2005-02-17 |
AU770319B2 (en) | 2004-02-19 |
AU770319C (en) | 2004-11-25 |
NZ507730A (en) | 2004-02-27 |
US20070135354A1 (en) | 2007-06-14 |
JP2002513762A (ja) | 2002-05-14 |
TWI252107B (en) | 2006-04-01 |
US7067489B2 (en) | 2006-06-27 |
BR9910251A (pt) | 2001-01-02 |
IL139247A0 (en) | 2001-11-25 |
WO1999056753A1 (en) | 1999-11-11 |
US6300314B1 (en) | 2001-10-09 |
PE20000481A1 (es) | 2000-06-13 |
NO20005488L (no) | 2001-01-04 |
AU2004202138A1 (en) | 2004-06-10 |
EP1075266A1 (en) | 2001-02-14 |
MY132924A (en) | 2007-10-31 |
NO20005488D0 (no) | 2000-10-31 |
US20020013279A1 (en) | 2002-01-31 |
AU3878199A (en) | 1999-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR023628A1 (es) | Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que | |
KR100638684B1 (ko) | 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도 | |
ATE173924T1 (de) | Zusammensetzungen für die rektale verabreichung enthaltend benzimidazole und fettsäuresalze | |
DE3584120D1 (de) | Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
KR100355686B1 (ko) | 세트로렐릭스동결건조물의제조방법 | |
PT85591A (en) | Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa | |
CA2392050A1 (en) | Pharmaceutical formulations containing zolmitriptan | |
RU94046426A (ru) | Фармацевтические композиции, способы лечения лейкоза, способ повышения уровней стволовых клеток, антагонист с - kit - лиганда, антисмысловая нуклеиновая кислота, способ лечения меланомы, способ усиления трансфекции, способ переноса гена, способ увеличения уровней периферической крови, способ повышения уровней тромбоцитов, способы модификации биологической функции, способ лечения анемии, способ улучшения приживления костного мозга, способ ускорения восстановления костного мозга, способ лечения лейкопении | |
JP2006504448A (ja) | ペプチド銅錯体および軟組織充填物を含有する組成物 | |
EP0047647A2 (en) | Pharmaceutical compositions for promoting the healing of wounds | |
US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
US6270750B1 (en) | Proline-, glycine- and lysine-based pharmaceutical composition useful in dental treatment both in the injectable form and in the formulation for topical use | |
JPH10265378A (ja) | 角膜上皮損傷治療剤 | |
US6863891B2 (en) | Oligopeptide lyophilisate, their preparation and use | |
WO1989010129A1 (en) | Pharmaceutical composition containing deoxyribonucleosides for wound healing | |
CN1245074A (zh) | 减弱阴道酸度的药剂和用途 | |
RU2002135669A (ru) | Олигопептиды | |
RU2005112720A (ru) | Фармацевтические композиции для улучшенного введения пептидов, происходящих от gp41 вич, и их использование в терапии | |
Hopps et al. | Demonstration and preliminary characterization of bone resorbing activity in freeze-dried gingiva of dogs | |
US9254306B2 (en) | Eye drops | |
AR005724A1 (es) | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple | |
EP1530455B1 (en) | A pharmaceutical formulation and its use in the treatment of inner ear diseases | |
HU892527D0 (en) | Process for producing of low molecular weight prourochinase derivatives and manufacturing of pharmaceutical compositions comprising them as active ingredients | |
JPS60233017A (ja) | 更年期障害を治療するためのゴナドリベリンおよびゴナドリベリンアゴニストの使用 | |
EP1009345A1 (en) | Skin aging and wound treatment using cell migration agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |